InvestorsHub Logo
Followers 86
Posts 12714
Boards Moderated 0
Alias Born 10/12/2010

Re: sulaco post# 197569

Sunday, 11/23/2014 11:41:45 AM

Sunday, November 23, 2014 11:41:45 AM

Post# of 345596

ESMO: Immunotherapy set to revolutionise cancer treatment

Immunotherapy is set to revolutionise the treatment of cancer, according to ESMO President Professor Rolf A. Stahel. His comments come as the ESMO Symposium on Immuno-Oncology 2014 is about to open in Geneva, Switzerland (21-22 November)

"We expect that the new possibilities of immunotherapy will substantially change the treatment of cancer," said Stahel, who is also Scientific Co-Chair of the meeting. "And this is not just in one disease, but across the board in many types of cancer. The ESMO Symposium on Immuno-Oncology will highlight all exciting immunotherapy topics which are now on the verge of entering clinical practice or are already practiced in some of the leading centres."



Sulaco, great post and I missed this post the other day. Interesting that the ESMO President Professor Rolf A. Stahel is also the Chairperson, along with Peregrine Pharmaceuticals KOL David in Session 9 re: Immuno-Oncology clinical studies across tumor types and within that session, David Carbone speaks re: "The immune system and lung cancer".

https://www.esmo.org/content/download/41727/790129/file/ESMO-Symposium-on-Immuno-Oncology-2014-Programme.pdf

--------------------------------------------------------


"Bavituximab is a first-in-class phosphatidylserine (PS)-targeting monoclonal antibody that is the cornerstone of a broad clinical
pipeline."
-- Big Pharmas nightmare... unless they are fortunate enough to have The Bavi Edge!

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent CDMO News